ENSG
The Ensign Group, Inc.
ENSG has lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over ENSG overall, supported by stronger valuation and stronger fundamentals.
ENSG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
ENSG's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ENSG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 22x | $187 | — |
| Cheap | 23x | $153 | -18% |
| Fair | 25x | $171 | -8.2% |
| Current | 28x | $187 | — |
| Expensive | 32x | $216 | +16% |
Historical ranges are pointers, not guarantees.
ENSG has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ENSG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ENSG, with profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over ENSG on the outlook, with more favorable profitability expectations.
ENSG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.60 | +28% |
| Q3 2026 | $6.72 | +20% |
| Q2 2026 | $6.38 | +16% |
| Q1 2026 | $6.14 | +16% |
| Q4 2025 | $5.84 | +14% |
| Q3 2025 | $5.60 | +36% |
| Q2 2025 | $5.52 | +42% |
| Q1 2025 | $5.30 | +40% |
| Q4 2024 | $5.12 | +40% |
ENSG's earnings per share have climbed steadily: $6.72 over the past year, up 20% from the year before, and higher year over year for eight quarters in a row.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ENSG on earnings, with stronger typical year-over-year growth.
ENSG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +14% |
| Q2 2026 | $1.4B | +17% |
| Q1 2026 | $1.4B | +18% |
| Q4 2025 | $1.4B | +20% |
| Q3 2025 | $1.3B | +20% |
| Q2 2025 | $1.2B | +18% |
| Q1 2025 | $1.2B | +16% |
| Q4 2024 | $1.1B | +15% |
ENSG's revenue has grown year over year every quarter since late 2020: $1.5B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.3% | +1.9 points |
| Q2 2026 | 8.5% | 0 points |
| Q1 2026 | 9% | +0.3 points |
| Q4 2025 | 9.1% | +0.2 points |
| Q3 2025 | 7.4% | -0.8 points |
| Q2 2025 | 8.5% | +0.2 points |
| Q1 2025 | 8.6% | +0.5 points |
| Q4 2024 | 8.9% | +6.6 points |
ENSG's operating margin was 9.3% last quarter, up 1.9 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ENSG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ENSG on profitability, with a higher operating margin.
ENSG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $240.2M | +57% |
| Q2 2026 | $172M | +10% |
| Q1 2026 | $100.2M | +39% |
| Q4 2025 | $183.3M | +82% |
| Q3 2025 | $153M | +14% |
| Q2 2025 | $155.7M | +102% |
| Q1 2025 | $72.2M | +105% |
| Q4 2024 | $100.5M | +18% |
ENSG has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ENSG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -180K shares |
| 1 year | +0.6% | +347K shares |
| 3 years | +3.4% | +2M shares |
| 5 years | +4.1% | +2.3M shares |
| Available history | +5.9% | +3.3M shares |
ENSG has 59M diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $7.4M |
| Q2 2026 | $40M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $9.2M |
| Q1 2025 | $10.8M |
| Q4 2023 | — |
ENSG spent $47M buying back its own shares over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ENSG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ENSG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.7x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
ENSG has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ENSG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.6 | Neutral |
| Stochastic | 70.3 | Neutral |
ENSG's weekly RSI is 60 (neutral) and its Stochastic is 70 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ENSG PE vs Healthcare Sector
| Metric | ENSG | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 26x | 7.4% above |
| PE % | 66 | 29 | 37 pts above |
ENSG has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ENSG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $177.5 | 5.1% above |
| 20 week MA | $175.8 | 6.1% above |
| 50 week MA | $181.0 | 3.1% above |
| 100 week MA | $165.7 | 13% above |
| 200 week MA | $139.9 | 33% above |
ENSG is in an uptrend: it's above all five of its weekly moving averages, and 33% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
ENSG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.7 | $72.8 | +63% |
| 2021 | $72.8 | $81.8 | +12% |
| 2022 | $81.8 | $95.0 | +16% |
| 2023 | $95.0 | $112.2 | +18% |
| 2024 | $112.2 | $134.0 | +19% |
| 2025 | $134.0 | $176.4 | +32% |
| 2026 YTD | $176.4 | $186.5 | +5.7% |
ENSG has finished every year since 2020 higher, and it's up 5.7% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ENSG on returns for 2026, with the stronger performance.